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Although anthrax toxin was identified as a major Bacillus anthracis virulence factor over 50 years ago,
defining the physiologically relevant targets has been challenging. Liu et al. demonstrate that intoxication
of myeloid-derived cells contributes to establishing infection but is not required for mortality resulting
from high toxin concentrations associated with end-stage disease.Anthrax toxin is a key virulence factor
of the lethal human pathogen Bacillus
anthracis. Three proteins, protective
antigen (PA), lethal factor (LF), and edema
factor (EF), assemble to form anthrax
toxin. PA binds cellular receptors CMG2/
ANTXR2 and/or TEM8/ANTXR1 and
translocates LF and EF into the host
cell cytoplasm. LF inactivates MEK/MKK
proteins via proteolytic cleavage, and EF
increases cAMP levels. Most cell types
express CMG2 and/or TEM8, and all cell
types are affected by alterations in p38/
JNK/ERK and cAMP signaling pathways,
though with variable outcomes (reviewed
in Moayeri and Leppla, 2009). This wide
range of receptor expression and the
pleiotropic effects of anthrax toxin have
made it challenging to define the specific
cellular and physiological targets that
account for B. anthracis virulence.
The discovery of anthrax toxin came
from experiments whereby injection of
sterile filtered plasma derived from mori-
bund rodents infected with B. anthracis
induced shock and death in a manner
similar to that associated with infection
(Smith and Keppie, 1954). As a result,
many subsequent in vivo studies on
anthrax toxin addressed the mechanism
by which it induces mortality in end-stage
disease. In contrast, in vitro studies were
strongly influenced by the finding that the
combination of PA and LF, referred to as
lethal toxin (LT), induced a rapid lytic death
in macrophages originating from a subset
of inbred mouse strains (Friedlander,
1986). Attempts were made to connect
the in vitro effects on macrophages to the
in vivo activity of LT resulting in mortality,
but subsequent evidence indicated that
these two activities are unlinked (Moayeri
and Leppla, 2009; Terra et al., 2010). The
combination of PA and EF, referred to as394 Cell Host & Microbe 8, November 18, 201edema toxin (ET), was also found to affect
immune cell function (O’Brien et al., 1985)
and cause death in mice, and, like LT,
these actions appeared to be unrelated
(Moayeri and Leppla, 2009). Therefore, a
model for anthrax toxin emerged in which
two distinct pathogenic roles were pro-
posed, an immunosuppressive role early
during infection and a role late in disease
that culminates in death of the host.
The findings of Liu et al. (2010) now
directly demonstrate an immunosuppres-
sive function for LT and ET on neutrophils
and macrophages in the promotion of
B. anthracis infection. Anthrax toxin tar-
geting of macrophages is mediated pre-
dominantly through the CMG2 receptor
(Banks et al., 2005; Cote et al., 2008).
Using CMG2-deficient mice, Liu et al.
confirm this finding and further show
that LT and ET utilize CMG2 to target
neutrophils. Importantly, the authors now
firmly establish that toxin-mediated inac-
tivation of these immune cells is important
for infection by demonstrating that
myeloid-specific CMG2-deficient mice
are resistant to spore challenge (Liu
et al., 2010).
The host response to bacterial infection
often includes influx of neutrophils fol-
lowed by a secondary monocytic/macro-
phage infiltration. Interestingly, the speed
and magnitude of neutrophil and mono-
cyte infiltration in response to B. anthracis
infection correlates with survival (Terra
et al., 2010), while depletion of either cell
type increases susceptibility of mice to
infection with the fully virulent Ames strain
(Cote et al., 2006). Further, increased
neutrophil infiltration was observed in
the liver and spleen during infection
with toxin-deficient B. anthracis strains
compared with toxin-expressing strains
(Heninger et al., 2006), and LT or ET inhibit0 ª2010 Elsevier Inc.macrophage and neutrophil function
in vitro (Moayeri and Leppla, 2009), sup-
porting an immunosuppressive role for
toxin. Here, Liu and colleagues examine
anthrax toxin interactions with neutrophils
during infection. When neutrophils were
depleted, myeloid-specific CMG-defi-
cient mice converted back to being sensi-
tive to spore challenge, establishing the
role of neutrophils in fighting off infection.
Although both LT and ET contributed to
immunosuppression, LT played a more
significant effect in blocking responses
by myeloid cells. Thus, B. anthracis uses
LT to block neutrophil responses in the
host, and in doing so allows the infection
to proceed.
As B. anthracis infections reach a fulmi-
nant state, systemic toxin levels increase
rapidly and contribute to the demise of
the host. This end-stage toxemia is
modeled experimentally by injection of a
high-dose of purified LT. When Liu and
colleagues challenged myeloid-specific
CMG2 knockout mice with LT, no change
to mortality was noted compared to wild-
type animals, demonstrating that lethality
is not dependent on toxin acting onmacro-
phages or neutrophils. Thus, indirect
effects associated with toxin targeting of
these cells, e.g., release of proinflamma-
tory cytokines, are not necessary to
mediate end-stage mortality. A likely alter-
native is that LT and ET directly target
vascular components, e.g., endothelial
cells, platelets, or cardiomyocytes. Indeed,
vascular collapse is observed in response
to LT or ET (Moayeri and Leppla, 2009).
New questions are raised by the find-
ings of Liu et al. First, is toxin activity on
other myeloid-derived cell types impor-
tant for establishment of infection? Prior
evidence indicates that macrophages
are also an important in vivo target, and
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macrophages protects mice from anthrax
(Cote et al., 2008). Thus, myeloid-derived
cell types, in addition to neutrophils, may
be necessary to mount a protective
immune response. Second, what function
do other cell types (e.g., mast cells, endo-
thelial cells) perform during infection, and
are these responses dependent on the
route of infection? Third, what are the
target cell types that govern end-stage
mortality, and, importantly, how do these
toxin-cell interactions affect virulence? In
mice, toxin is not required for end-stage
disease if bacilli can overcome host
immunity (i.e., through capsule produc-
tion) (Heninger et al., 2006), raising the
possibility that shock induced by toxin
may not be required for virulence.
Regardless, understanding mechanismsof toxin-induced mortality is relevant for
the development of treatment strategies
for end-stage toxemia in humans. Fourth,
what roles do inflammatory mediators
perform during early or late-stage dis-
ease? Tissue-specific anthrax toxin re-
ceptor knockout mice, like those used
by Liu et al., represent a powerful tool to
address such questions and will quicken
the pace of research aimed at under-
standing of the physiologically relevant
roles of toxin in anthrax.REFERENCES
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